International Journal of Computational and Experimental Science and ENgineering (IJCESEN)

Vol. 10-No.4 (2024) pp. 4227-4239
http://www.ijcesen.com



ISSN: 2149-9144

Research Article

Collaboration Between Laboratory, Nursing, and Pharmacy Teams in the Early Detection and Management of Drug-Induced Organ Toxicity

Meshal Moutir A Alenezi[1]*, Alanazi, Jawaher Khunaysir W[2], Ghadah Saud Almansour[3], Adel Badah Alkuwaykibi[4] , Ahmed Nafea Abdullah Alenazi[5] , Maha Ahmed Bnyan Alshammery[6] , Raghad Mohammed Fahad Alanazi[7] , Fatimah Oudah Fayiz Alruwaili[8], Ahmed Falah Dabis Alrashdi[9], Thanyah Saeed Hajis Alruwaili[10]

[1]Laboratory Senior Specialist (Hematology), Maternity and Children Hospital, Arar, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia,
* **Corresponding Author Email:** Mlt.Meshal@gmail.com- **ORCID:** 0000-0002-5247-7324

[2]Medical Laboratory Specialist, Maternity and Pediatric Hospital, Arar, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia
Email: Jawaher.alenzi@gmail.com - **ORCID:** 0000-0002-1147-7013

[3]Laboratory Specialist, Maternity and Children's Hospital, Arar, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia
Email: galmanour@moh.gov.sa- **ORCID:** 0000-0002-1147-2243

[4]Laboratory Technician, Al Jouf Health Cluster, Ministry of Health, Sakaka, Al Jouf Region, Saudi Arabia
Email: aalkwekbe@moh.gov.sa - **ORCID:** 0000-0002-1147-7033

[5]Pharmacist, Hail General Hospital, Hail Health Cluster, Ministry of Health, Hail, Hail Region, Saudi Arabia
Email: analenazi@moh.gov.sa- **ORCID:** 0000-0002-1147-7043

[6]Nursing Specialist, Northern Medical Tower, Arar, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia
Email: Melshamry@moh.gov.sa- **ORCID:** 0000-0002-1147-7053

[7]Specialist Nursing and Midwifery, Maternity and Children Hospital (Neonatal Intensive Care Unit), Arar, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia
Email: ralanazi63@gmail.com - **ORCID:** 0000-0002-1147-7063

[8]Nursing Technician, Eradah and Mental Health Complex, Arar, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia
Email: fatimahoa@moh.gov.sa - **ORCID:** 0000-0002-1147-7073

[9]Specialist Nursing, Al Hayit General Hospital, Hail Health Cluster, Ministry of Health, Al Hayit, Hail Region, Saudi Arabia
Email: Ahfaalrashdi@moh.gov.sa- **ORCID:** 0000-0002-1147-7083

[10]Pharmacist, Suwair General Hospital, Al Jouf Health Cluster, Ministry of Health, Suwair, Al Jouf Region, Saudi Arabia
Email: talrwulili@moh.gov.sa - **ORCID:** 0000-0002-1147-7093

Article Info:

DOI: 10.22399/ijcesen.5012
Received : 02 June 2024
Accepted : 30 June 2024

Keywords

Drug-induced organ toxicity,
interprofessional collaboration,
laboratory medicine,
nursing,
pharmacy,
hepatotoxicity

Abstract:

Collaboration between laboratory, nursing, and pharmacy teams plays a pivotal role in the early detection and management of drug-induced organ toxicity, a critical aspect of patient safety and effective healthcare. Laboratories are responsible for conducting various tests to identify biomarkers and physiological changes indicative of organ toxicity, providing essential data that can inform clinical decisions. When nurses are integral to this process, they actively monitor patients for signs of adverse drug reactions and report any changes in their condition. This real-time communication ensures that laboratory findings are swiftly translated into actionable insights, bridging the gap between diagnostic results and patient care. Pharmacy teams further enhance this collaborative approach by offering expertise in pharmacotherapy and medication management. They evaluate patient medication regimens to identify potential drug interactions and contraindications while recommending alternatives when necessary. Through interdisciplinary rounds and discussions, pharmacists, nurses, and laboratory professionals can establish protocols for monitoring patients at risk for organ toxicity, developing a coordinated strategy for both prevention and intervention. By fostering a team-oriented environment, healthcare providers can enhance early detection efforts, optimize treatment strategies, and ultimately improve patient outcomes in the management of drug-induced organ toxicity.

1. Introduction

The contemporary healthcare landscape is characterized by an ever-expanding pharmacopoeia, with novel therapeutic agents entering clinical practice at an unprecedented rate. While these medications offer remarkable benefits in the treatment of acute and chronic diseases, they simultaneously introduce significant risks, chief among them being drug-induced organ toxicity (DIOT). Drug-induced organ toxicity represents one of the most challenging and pervasive problems in modern medicine, affecting virtually every organ system and contributing substantially to patient morbidity, mortality, and healthcare expenditure worldwide. The liver, as the primary site of drug metabolism, bears the brunt of this toxic burden, with drug-induced liver injury (DILI) accounting for approximately 10% to 15% of acute liver failure cases in the United States and representing the most common cause of post-market drug withdrawals over the past five decades [1]. Similarly, the kidneys, with their high blood flow and role in drug excretion, remain exquisitely vulnerable to nephrotoxic insults, while the heart, lungs, and other organs face varying degrees of pharmacological vulnerability depending on drug class, dosage, duration of exposure, and host factors [2].

The clinical and economic implications of DIOT extend far beyond the immediate patient encounter. For the affected individual, drug-induced organ damage may manifest as asymptomatic laboratory abnormalities, progressive organ dysfunction requiring long-term medical management, or catastrophic organ failure necessitating transplantation or resulting in death. For healthcare systems, DIOT translates into prolonged hospitalizations, intensive care unit admissions, costly interventions, and significant medicolegal liability. From a public health perspective, the burden of DIOT is compounded by the aging population, the rising prevalence of polypharmacy, and the increasing complexity of therapeutic regimens for chronic diseases such as cancer, cardiovascular disease, diabetes, and autoimmune disorders [3]. Older adults, in particular, face disproportionately high risks due to age-related changes in drug metabolism and excretion, the presence of multiple comorbidities, and the consequent need for combination therapies that amplify the potential for drug-drug interactions and cumulative organ injury [4].

The fundamental challenge in mitigating DIOT lies not in the absence of monitoring tools but in the fragmented and reactive nature of current detection and management workflows. Traditional approaches to drug safety monitoring have relied heavily on the recognition of overt clinical signs and symptoms—jaundice, oliguria, dyspnea, or altered mental status—that typically signify advanced organ injury rather than early, potentially reversible dysfunction. By the time such manifestations become apparent, the window for effective intervention has often closed, and irreversible damage may already have occurred [5]. Laboratory biomarkers, including serum aminotransferases, alkaline phosphatase, bilirubin, serum creatinine, and estimated glomerular filtration rate, have long served as the cornerstone of drug safety monitoring, yet their utility has been constrained by fragmented interpretation, delayed communication, and inconsistent integration into clinical decision-making [6].

In recent years, the scientific community has made substantial progress in identifying and validating

novel biomarkers capable of detecting organ injury at much earlier stages than conventional tests. Urinary biomarkers such as kidney injury molecule-1 (KIM-1), clusterin, neutrophil gelatinase-associated lipocalin (NGAL), and cystatin C have demonstrated remarkable sensitivity in identifying subclinical nephrotoxicity days or even weeks before changes in serum creatinine become detectable [7]. For hepatotoxicity, emerging biomarkers including microRNAs, glutamate dehydrogenase (GLDH), and high-mobility group box-1 (HMGB1) protein offer the potential to distinguish between different patterns and mechanisms of liver injury, thereby guiding more targeted interventions [8]. These advances in diagnostic capability, however, have not been matched by corresponding improvements in the organizational and collaborative frameworks necessary to translate biomarker information into timely, effective clinical action.

The integration of these three professional groups into a cohesive, collaborative workflow represents a paradigm shift from traditional siloed approaches to drug safety monitoring. In conventional models, responsibility for DIOT detection and management is diffusely distributed, with no single professional group assuming clear accountability for the entire process. Laboratory results may be generated and reported without contextual interpretation or direct communication to the clinicians best positioned to act upon them. Nursing assessments of patient status may not be systematically integrated with laboratory data to create a comprehensive picture of organ function. Pharmacists may identify potential drug safety concerns but lack the authority or communication pathways to implement preventive measures. The cumulative effect of these disconnects is a system that is reactive rather than proactive, fragmented rather than integrated, and ultimately less effective in protecting patients from preventable harm [9].

2. The Pathophysiological Basis and Clinical Spectrum of Drug-Induced Organ Toxicity

Drug-induced organ toxicity encompasses a diverse array of pathological processes through which pharmacological agents cause structural or functional damage to bodily organs. Understanding these mechanisms is essential for appreciating the rationale behind biomarker selection, the timing of monitoring interventions, and the potential for collaborative detection and management strategies. While virtually every organ system may be affected by drug toxicity, the liver and kidneys deserve particular attention due to their central roles in drug metabolism and excretion, their unique vulnerabilities to toxic injury, and the frequency with which they are affected in clinical practice [10].

The liver, as the body's primary detoxification organ, processes the vast majority of xenobiotics through phase I and phase II metabolic pathways. Phase I reactions, catalyzed primarily by cytochrome P450 (CYP) enzymes, introduce functional groups onto drug molecules through oxidation, reduction, or hydrolysis, often resulting in the formation of reactive intermediates. Phase II reactions involve conjugation of these metabolites with endogenous substrates such as glucuronic acid, sulfate, or glutathione, producing water-soluble compounds suitable for biliary or renal excretion. This sophisticated metabolic machinery, while essential for drug elimination, simultaneously creates vulnerability to toxic injury through several distinct mechanisms [11].

The most extensively characterized mechanism of drug-induced hepatotoxicity involves the metabolic activation of drugs to reactive metabolites that form covalent bonds with cellular macromolecules. Acetaminophen hepatotoxicity represents the prototypical example of this mechanism. At therapeutic doses, acetaminophen is primarily metabolized through glucuronidation and sulfation pathways, with a small fraction undergoing CYP2E1-mediated oxidation to form the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI). Under normal conditions, NAPQI is rapidly detoxified through conjugation with glutathione and excreted. Following overdose, however, glutathione stores become depleted, allowing NAPQI to accumulate and bind covalently to mitochondrial proteins, leading to mitochondrial dysfunction, ATP depletion, and ultimately hepatocyte necrosis [12]. This mechanism explains the characteristic centrilobular pattern of acetaminophen-induced liver injury, reflecting the high concentration of CYP2E1 in perivenular hepatocytes.

Beyond direct hepatocyte injury, drugs may cause liver damage through mitochondrial dysfunction, oxidative stress, and immune-mediated mechanisms. Mitochondrial toxicity, exemplified by drugs such as valproic acid and linezolid, results from impairment of fatty acid oxidation, disruption of the electron transport chain, or inhibition of mitochondrial DNA synthesis. The consequent depletion of cellular energy stores and accumulation of toxic metabolites triggers hepatocyte apoptosis and necrosis, with the severity of injury depending on the degree of mitochondrial impairment and the capacity for cellular adaptation [13]. Oxidative stress, arising from an imbalance between reactive oxygen species generation and

antioxidant defense mechanisms, contributes to hepatotoxicity through lipid peroxidation, protein oxidation, and DNA damage, amplifying the injurious effects of other toxic mechanisms.

Immune-mediated drug-induced liver injury represents a distinct and clinically challenging category, characterized by unpredictable onset, lack of clear dose-response relationships, and variable latency periods ranging from days to months after drug exposure. The prevailing hypothesis suggests that drugs or their reactive metabolites may act as haptens, binding covalently to hepatic proteins and generating neoantigens that trigger adaptive immune responses in genetically susceptible individuals. This mechanism explains the association between certain human leukocyte antigen (HLA) genotypes and increased risk of DILI from specific drugs, such as HLA-B*5701 with flucloxacillin-induced liver injury and HLA-DRB1*1501 with amoxicillin-clavulanate hepatotoxicity [14]. The clinical presentation of immune-mediated DILI often includes features of hypersensitivity such as fever, rash, and eosinophilia, and may resemble autoimmune hepatitis with positive autoantibodies and interface hepatitis on histopathological examination.

Drug-induced nephrotoxicity shares some mechanistic features with hepatotoxicity while exhibiting unique characteristics related to renal physiology and anatomy. The kidneys receive approximately 25% of cardiac output, exposing them to high concentrations of drugs and metabolites delivered through the systemic circulation. The proximal tubule, responsible for active secretion and reabsorption of numerous compounds, is particularly vulnerable to toxic injury due to its high metabolic activity, transport capacity, and concentrating function. Drugs may injure the kidneys through multiple mechanisms including direct tubular toxicity, intratubular obstruction, interstitial nephritis, glomerular injury, and thrombotic microangiopathy [15].

Cisplatin-induced nephrotoxicity illustrates the complex interplay of mechanisms underlying renal injury from anticancer agents. Following uptake into proximal tubular cells primarily through the organic cation transporter 2 (OCT2), cisplatin undergoes intracellular aquation to form highly reactive species that bind to DNA, proteins, and phospholipids. The resulting cellular stress triggers multiple pathways of injury, including mitochondrial dysfunction with ATP depletion, oxidative stress from reactive oxygen species generation, activation of apoptotic and necrotic cell death pathways, and inflammatory responses that amplify tissue damage [16]. These mechanisms explain both the dose-dependent nature of cisplatin nephrotoxicity and the potential for cumulative injury with repeated treatment cycles, as tubular cells may not fully recover between doses.

Contrast-induced acute kidney injury (CI-AKI) represents another clinically significant form of nephrotoxicity with important implications for interprofessional collaboration. The pathogenesis of CI-AKI involves a combination of direct tubular toxicity from contrast media, renal medullary ischemia resulting from vasoconstrictive effects, and oxidative stress from reactive oxygen species generation. Risk factors for CI-AKI include pre-existing chronic kidney disease, diabetes mellitus, advanced age, volume depletion, hemodynamic instability, and concurrent use of other nephrotoxic medications [17]. The prevention of CI-AKI requires coordinated action across multiple disciplines, with nursing professionals assessing baseline renal function and volume status, pharmacy professionals evaluating medication regimens for nephrotoxic agents and holding appropriate drugs before contrast administration, and radiology professionals selecting contrast type and volume while ensuring adequate hydration periprocedurally.

Drug-induced organ toxicity extends beyond the liver and kidneys to affect virtually every organ system. Cardiotoxicity from anthracyclines, trastuzumab, and tyrosine kinase inhibitors may manifest as left ventricular dysfunction, heart failure, or arrhythmias with potentially life-threatening consequences. Pulmonary toxicity from amiodarone, bleomycin, and nitrofurantoin can produce interstitial lung disease, pulmonary fibrosis, or acute pneumonitis. Neurotoxicity from vinca alkaloids, platinum compounds, and antiretroviral agents may cause peripheral neuropathy, autonomic dysfunction, or central nervous system effects ranging from cognitive impairment to seizures. The diversity of organ systems affected and mechanisms involved underscores the need for comprehensive, multidisciplinary approaches to drug safety monitoring that extend beyond any single organ or biomarker.

3. Biomarkers for Early Detection of Drug-Induced Organ Toxicity

The evolution of biomarkers for drug-induced organ toxicity represents one of the most significant advances in clinical pharmacology and patient safety over the past several decades. Traditional biomarkers, while valuable, have been limited by their late appearance in the course of organ injury, their lack of specificity for particular injury mechanisms, and their vulnerability to confounding

factors unrelated to drug toxicity. The emergence of novel biomarkers with enhanced sensitivity, specificity, and mechanistic interpretability has created unprecedented opportunities for early detection and intervention, but has also introduced new complexities regarding their selection, interpretation, and integration into clinical workflows [18].

Conventional liver biomarkers have served as the foundation for DILI detection and monitoring for more than half a century. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), enzymes released from damaged hepatocytes, remain the most widely used indicators of hepatocellular injury. ALT, localized primarily in the cytoplasm of hepatocytes, offers greater specificity for liver injury than AST, which is also present in cardiac and skeletal muscle, erythrocytes, and other tissues. The pattern and magnitude of aminotransferase elevation provide important diagnostic information, with marked elevations predominantly reflecting hepatocellular necrosis and more modest elevations potentially indicating a broader range of liver pathologies [19]. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), enzymes associated with the biliary epithelium, serve as markers of cholestatic injury, with disproportionate elevation relative to aminotransferases suggesting impairment of bile formation or flow. Total bilirubin and its fractions provide information about hepatic synthetic and excretory function, with the combination of elevated aminotransferases and elevated bilirubin (so-called "Hy's Law") carrying particularly poor prognostic significance in DILI [20].

Despite their established utility, conventional liver biomarkers possess important limitations that constrain their effectiveness for early DILI detection. Aminotransferase elevations may not occur until substantial hepatocellular injury has already developed, and mild to moderate elevations lack specificity for DILI, occurring commonly in viral hepatitis, ischemic liver injury, non-alcoholic fatty liver disease, and numerous other conditions. Furthermore, conventional biomarkers provide limited mechanistic information, making it difficult to distinguish between different patterns of liver injury or to predict which patients will progress to severe outcomes versus those who will recover spontaneously despite continued drug exposure.

The search for improved DILI biomarkers has yielded several promising candidates with potential for earlier detection and enhanced mechanistic insight. Glutamate dehydrogenase (GLDH), a mitochondrial enzyme enriched in the centrilobular region of the liver, has demonstrated utility in detecting hepatocellular injury with greater sensitivity and specificity than ALT in some contexts. Because GLDH release reflects mitochondrial disruption specifically, it may offer advantages in identifying injury mechanisms involving mitochondrial dysfunction and in distinguishing true hepatocellular injury from enzyme elevations due to other causes [21]. High-mobility group box-1 (HMGB1) protein, a nuclear protein released from necrotic cells and actively secreted by activated immune cells, serves as a biomarker of both cell death and inflammation, providing information about injury mechanisms beyond simple hepatocellular damage. The acetylated form of HMGB1, derived from activated immune cells, may be particularly useful in identifying immune-mediated DILI and distinguishing it from direct hepatotoxic injury.

MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression and are released into the circulation following cell injury, represent one of the most exciting developments in DILI biomarker research. Specific miRNAs exhibit tissue-enriched expression patterns, with miR-122 highly enriched in liver, miR-133 in cardiac muscle, and miR-192 in kidney, raising the possibility of organ-specific injury detection. Studies have demonstrated that miR-122 elevations precede ALT elevations in acetaminophen-induced liver injury and correlate with the extent of hepatocellular necrosis on histopathological examination [22]. The stability of miRNAs in biological samples, their conservation across species, and their potential for detection using high-throughput platforms make them attractive candidates for clinical implementation, though standardization and validation efforts remain ongoing.

For drug-induced nephrotoxicity, the limitations of conventional biomarkers are even more pronounced than for hepatotoxicity. Serum creatinine, the most widely used clinical marker of renal function, is a late and insensitive indicator of kidney injury, typically not increasing until substantial loss of functional nephrons has occurred. Creatinine is also influenced by numerous non-renal factors including muscle mass, dietary protein intake, age, sex, and certain medications that interfere with tubular secretion. The urine albumin-to-creatinine ratio, while valuable for detecting glomerular injury, lacks sensitivity for tubular damage and may not increase until injury is well-established [23].

The qualification of novel urinary biomarkers for nephrotoxicity detection represents a major achievement of regulatory science over the past decade. Kidney injury molecule-1 (KIM-1), a transmembrane protein markedly upregulated in proximal tubular cells following ischemic or toxic

injury, has emerged as one of the most extensively validated biomarkers of early kidney damage. Following injury, the extracellular domain of KIM-1 is cleaved and shed into the urine, where its concentration correlates with the severity of tubular injury and predicts subsequent decline in renal function. Studies in patients receiving cisplatin chemotherapy have demonstrated that urinary KIM-1 elevations precede serum creatinine increases by days to weeks, providing a critical window for intervention before irreversible damage occurs [24]. Clusterin, a glycoprotein involved in cell-cell interactions and tissue remodeling, represents another valuable urinary biomarker for nephrotoxicity detection. Expressed at low levels in healthy kidneys, clusterin is markedly upregulated in response to tubular injury and secreted into the urine, where its concentration reflects the extent and severity of damage. The utility of clusterin has been demonstrated across multiple nephrotoxic agents and experimental models, with studies showing that urinary clusterin elevations correlate with histopathological evidence of tubular injury and predict functional decline earlier than conventional markers [25]. The regulatory qualification of KIM-1 and clusterin by the U.S. Food and Drug Administration and European Medicines Agency for voluntary use in preclinical safety studies and clinical trials reflects the growing acceptance of these biomarkers as valid indicators of drug-induced kidney injury.

Neutrophil gelatinase-associated lipocalin (NGAL), a protein released from injured tubular epithelial cells and neutrophils, provides complementary information to KIM-1 and clusterin in nephrotoxicity assessment. NGAL elevations occur very early after tubular injury, often within hours, making this biomarker particularly valuable for detecting acute kidney injury in hospitalized patients. The prognostic significance of NGAL has been demonstrated across multiple clinical settings, with higher urinary concentrations predicting more severe renal dysfunction, longer hospital stays, and increased mortality [26]. Cystatin C, a cysteine protease inhibitor produced at a constant rate by all nucleated cells, freely filtered by the glomerulus, and completely reabsorbed and catabolized by proximal tubular cells, serves as an alternative to creatinine for estimating glomerular filtration rate. Unlike creatinine, cystatin C is not influenced by muscle mass, age, or sex, providing more accurate assessment of renal function in patients with chronic illness, sarcopenia, or other conditions that confound creatinine interpretation.

The application of novel biomarkers in clinical practice requires careful consideration of pre-analytical variables, assay performance characteristics, and interpretive frameworks. Unlike conventional biomarkers with decades of clinical use and well-established reference ranges, many novel biomarkers lack standardized assays, normative data across diverse populations, and validated cut-points for clinical decision-making. The integration of multiple biomarkers into composite panels, analogous to the "biomarker panels" used in cardiac ischemia assessment, may enhance diagnostic performance by capturing different aspects of injury pathophysiology and compensating for individual biomarker limitations [27]. The development of point-of-care testing platforms for novel biomarkers could further accelerate clinical implementation by enabling real-time results at the bedside, facilitating immediate clinical action without delays for central laboratory processing.

4. The Distinct and Complementary Roles of Laboratory, Nursing, and Pharmacy Professionals

The effective detection and management of drug-induced organ toxicity requires the coordinated application of distinct expertise from multiple professional groups, each contributing unique perspectives, skills, and responsibilities to the collaborative enterprise. Understanding these complementary roles is essential for designing workflows that leverage the full potential of interprofessional teamwork while respecting the scope of practice and professional autonomy of each discipline.

The laboratory professional serves as the foundation upon which biomarker-based DIOT detection rests, providing the analytical expertise, quality oversight, and interpretive guidance necessary to ensure that laboratory data accurately reflect patient status and support clinical decision-making. Within the clinical laboratory, medical laboratory scientists and clinical pathologists perform the technical work of specimen analysis, operating sophisticated instrumentation, verifying the accuracy and precision of test results, and troubleshooting analytical problems that could compromise data quality. The complexity of modern biomarker assays, many of which employ immunoassay, mass spectrometry, or molecular techniques requiring specialized expertise, underscores the essential role of laboratory professionals in generating reliable results [28].

Beyond analytical functions, laboratory professionals contribute to DIOT detection through their knowledge of pre-analytical variables that can influence test results. Specimen collection techniques, processing times, storage conditions,

and transport procedures all affect biomarker stability and measurement accuracy, with different analytes exhibiting varying degrees of vulnerability to pre-analytical degradation. Laboratory professionals educate nursing and other clinical staff about proper specimen handling, monitor compliance with collection protocols, and interpret results within the context of potential pre-analytical artifacts. For novel biomarkers with limited clinical experience, laboratory professionals may provide particular value by identifying patterns suggestive of pre-analytical problems and recommending corrective actions before erroneous results influence patient care.

The interpretive role of laboratory professionals extends to the contextualization of biomarker results within reference population norms, expected biological variation, and clinically significant change thresholds. Unlike binary test results with clear normal-abnormal cutoffs, many biomarkers exhibit continuous distributions with overlapping values between healthy and diseased populations, requiring probabilistic interpretation based on pre-test probability, magnitude of change, and temporal patterns. Laboratory professionals contribute to this interpretive process by providing delta-check alerts for significant changes from previous values, flagging results that exceed critical thresholds requiring immediate clinical attention, and offering consultative expertise for complex cases involving multiple biomarkers or atypical result patterns [29].

The nursing professional occupies a uniquely positioned role at the intersection of direct patient care, clinical observation, and interprofessional communication. Unlike laboratory or pharmacy professionals whose interactions with patients may be intermittent or indirect, nurses maintain continuous presence at the bedside, conducting ongoing assessments of patient status, monitoring for subtle changes in clinical condition, and establishing therapeutic relationships that facilitate patient education and engagement in safety monitoring. This frontline position enables nurses to detect early manifestations of organ toxicity that may precede laboratory abnormalities or occur in settings where laboratory monitoring is not immediately available.

The nursing assessment for potential DIOT encompasses both systematic data collection and intuitive clinical judgment developed through experience and pattern recognition. Vital sign monitoring may reveal fever suggesting drug hypersensitivity, hypertension or fluid retention indicating renal impairment, or tachycardia and hypotension signaling cardiovascular compromise. Physical examination findings, including jaundice, scleral icterus, hepatomegaly, peripheral edema, or changes in urine output and character, provide important clues to organ dysfunction that complement and contextualize laboratory data. The astute nurse integrates these observations with knowledge of the patient's medication regimen, underlying conditions, and risk factors for drug toxicity, forming a comprehensive clinical picture that informs subsequent diagnostic and therapeutic interventions [30].

The nursing role in specimen collection and handling directly impacts the quality and reliability of biomarker measurements. Ensuring proper timing of specimen collection relative to drug administration, verifying patient identification and specimen labeling accuracy, using appropriate collection tubes and techniques, and facilitating timely transport to the laboratory all fall within the nursing scope of practice. For specialized testing such as therapeutic drug monitoring, nurses may coordinate collection of peak and trough levels at precisely specified intervals, communicate with patients about medication timing, and document collection times accurately to enable pharmacokinetic interpretation. The meticulous attention to these details by nursing professionals prevents pre-analytical errors that could otherwise compromise biomarker validity and lead to incorrect clinical decisions.

Patient education represents another critical nursing contribution to DIOT detection and management. Nurses explain to patients the purpose and importance of laboratory monitoring, the symptoms of organ dysfunction that warrant prompt reporting, and the medication adherence practices that minimize toxicity risk. For patients receiving high-risk medications at home, nursing education may include instruction in self-monitoring techniques, criteria for seeking medical attention, and strategies for medication organization and adherence. This educational role becomes particularly important when patients transition between care settings, as accurate medication reconciliation and clear communication about monitoring plans reduce the risk of gaps in safety surveillance [31].

The pharmacy professional contributes specialized knowledge of drug pharmacology, toxicokinetics, drug-drug interactions, and evidence-based prescribing practices essential for comprehensive DIOT risk assessment and management. Clinical pharmacists, through their understanding of drug absorption, distribution, metabolism, and excretion, can identify patients at increased risk for toxicity based on age, organ function, genetic polymorphisms, and concomitant medications. This risk stratification enables targeted monitoring intensity, with high-risk patients receiving more

frequent biomarker assessment and closer clinical follow-up than those at lower risk.

Proactive medication review by pharmacists identifies potential drug-drug interactions that may amplify organ toxicity through pharmacokinetic or pharmacodynamic mechanisms. For nephrotoxicity prevention, pharmacists may identify combinations of medications with additive or synergistic effects on renal function, such as concurrent use of nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, and diuretics—the so-called "triple whammy" associated with increased acute kidney injury risk. For hepatotoxicity prevention, pharmacists assess potential interactions involving CYP enzyme inhibition or induction that could alter production of toxic metabolites, as well as combinations of potentially hepatotoxic drugs that may produce cumulative injury exceeding the effect of any single agent [32].

Therapeutic drug monitoring (TDM), a specialized pharmacy function, optimizes drug dosing to maintain concentrations within the therapeutic window while avoiding toxic levels. For drugs with narrow therapeutic indices such as aminoglycosides, vancomycin, calcineurin inhibitors, and certain anticonvulsants, TDM provides objective guidance for dose adjustment based on measured drug concentrations in conjunction with assessment of organ function and clinical response. Pharmacists interpret TDM results in the context of dosing history, sampling timing, patient characteristics, and concurrent medications, generating specific recommendations for dose modification, interval adjustment, or alternative therapy selection. The integration of TDM with biomarker monitoring for organ toxicity creates a comprehensive safety surveillance system that addresses both drug exposure and drug effect [33].

When biomarker elevations or clinical findings suggest developing organ toxicity, pharmacists contribute to management decisions through evidence-based recommendations for dose reduction, drug discontinuation, or alternative agent selection. For drug-induced liver injury, pharmacists assess the pattern and severity of biomarker abnormalities, review published literature on hepatotoxicity risk for implicated agents, and consider the availability and effectiveness of therapeutic alternatives. For immune-mediated DILI, pharmacists may recommend corticosteroid therapy and advise on dosing, duration, and monitoring parameters. For nephrotoxicity, pharmacists evaluate the contribution of individual drugs to renal impairment, prioritize interventions based on the likelihood of causality and the availability of alternatives, and design gradual dose reduction schedules that minimize the risk of withdrawal effects or disease exacerbation.

5. A Comprehensive Framework for Interprofessional Collaboration in DIOT Detection and Management

The preceding analysis of distinct professional roles provides the foundation for constructing an integrated collaborative framework that coordinates laboratory, nursing, and pharmacy contributions into a unified approach to DIOT detection and management. Such a framework must address multiple dimensions of collaborative practice, including structural elements (who does what), process elements (how work flows), communication elements (how information is shared), and accountability elements (how performance is monitored and improved). The framework proposed here draws upon evidence from successful collaborative models in other clinical contexts while adapting specifically to the unique requirements of drug safety monitoring.

The structural foundation of effective interprofessional collaboration lies in clearly defined roles and responsibilities that leverage the unique expertise of each discipline while avoiding duplication, gaps, or conflicts in task assignment. Within the proposed framework, the laboratory team assumes primary responsibility for ensuring analytical quality, establishing and maintaining reference intervals, developing and validating biomarker assays, and providing interpretive guidance for complex or atypical results. The nursing team takes ownership of frontline patient assessment, specimen collection and handling, patient education, and communication of clinical observations to other team members. The pharmacy team leads medication review and reconciliation, risk stratification, therapeutic drug monitoring, and evidence-based recommendations for toxicity prevention and management [34].

These role definitions, while providing clarity and structure, should not be interpreted as rigid boundaries limiting professional practice. Effective collaboration requires flexibility and adaptability, with team members stepping outside narrowly defined roles when circumstances demand and mutual respect enabling professionals to contribute beyond formal scope-of-practice designations. A nurse who identifies a potential drug interaction through medication reconciliation should be empowered to communicate that observation to the pharmacy team without concern about overstepping professional boundaries. A pharmacist who notes

subtle clinical findings during patient interview should be encouraged to document and communicate those observations to nursing colleagues. This fluidity of professional contribution, grounded in mutual respect and shared commitment to patient safety, distinguishes truly collaborative teams from merely co-located professional groups.

The process dimension of collaborative DIOT management encompasses the sequential and parallel activities through which detection and intervention occur. The process begins with risk assessment at the time of medication prescribing, with pharmacists reviewing patient characteristics, organ function, concurrent medications, and drug-specific toxicity profiles to generate a baseline risk stratification that informs monitoring intensity and frequency. For high-risk patients or medications, this assessment may trigger enhanced monitoring protocols specifying the type, timing, and frequency of biomarker measurements, as well as clinical parameters requiring nursing assessment and documentation.

The monitoring phase involves coordinated execution of laboratory testing and clinical assessment according to protocol specifications. Nursing professionals ensure that specimens are collected at appropriate times, using correct techniques, and with proper documentation of relevant variables such as time since last dose, concurrent symptoms, and changes in patient status. Laboratory professionals perform biomarker analyses according to validated protocols, verify result accuracy through quality control procedures, and report results through the electronic health record with appropriate flags for values exceeding reference intervals or critical thresholds. The integration of laboratory and nursing data within the electronic health record enables comprehensive assessment of organ status, with biomarker trends displayed alongside clinical observations and medication administration records.

The interpretation phase transforms raw data into actionable information through collaborative synthesis of multiple data sources. Automated clinical decision support tools, integrated within the electronic health record, may provide initial triage by flagging abnormal results, identifying significant changes from baseline, and generating alerts for values meeting critical criteria. However, automated tools cannot substitute for human judgment in complex cases, and the framework specifies pathways for escalating concerning findings to appropriate team members for review. A pharmacist may receive automated notification of rising serum creatinine in a patient receiving multiple nephrotoxic medications, prompting detailed medication review and development of preliminary recommendations. A nurse may receive notification of elevated aminotransferases in a patient reporting new fatigue and nausea, prompting more focused clinical assessment and communication of findings to the medical team [35].

The intervention phase translates collaborative interpretation into coordinated action to prevent or mitigate organ injury. For early, mild abnormalities, intervention may involve enhanced monitoring with more frequent biomarker assessment and closer clinical observation, allowing continued therapy with the putative offending agent while watching for progression. For more significant abnormalities, intervention may include dose reduction, temporary drug hold, or permanent discontinuation, with decisions guided by the severity of injury, the likelihood of drug causality, the availability and effectiveness of therapeutic alternatives, and the patient's preferences and values. For severe or progressive injury despite drug modification, intervention escalates to include specific therapies directed at the underlying injury mechanism, such as N-acetylcysteine for acetaminophen hepatotoxicity, corticosteroids for immune-mediated DILI, or renal replacement therapy for advanced acute kidney injury.

Communication represents the critical connective tissue binding the collaborative framework together, ensuring that information flows efficiently and reliably between team members and that decisions are transmitted clearly to all affected parties. Structured communication tools, adapted from high-reliability industries such as aviation and nuclear power, enhance the effectiveness of interprofessional communication by standardizing content, format, and expectations. The SBAR (Situation, Background, Assessment, Recommendation) technique, widely implemented in healthcare settings, provides a framework for concise, complete communication that ensures all relevant information is transmitted and received. A nurse communicating concerns about possible DILI might structure the message as: "Situation: I'm concerned about Mr. Smith in room 412 who may be developing liver injury from his isoniazid. Background: He started INH two weeks ago for latent TB, baseline LFTs were normal, and he has no prior liver disease. Assessment: His ALT today is 250, up from 45 last week, and he reports new fatigue and decreased appetite. Recommendation: I think we should consider holding the INH and consulting pharmacy for alternative therapy options."

The electronic health record serves as both repository for collaborative documentation and

platform for asynchronous communication between team members. Laboratory results, medication administration records, clinical assessment findings, and interprofessional communications are aggregated within the record, creating a comprehensive data source accessible to all team members regardless of location or shift assignment. Structured data entry, including flowsheets for serial biomarker measurements, standardized assessments for organ toxicity symptoms, and discrete fields for medication reconciliation, enables data aggregation and analysis that would be impossible with free-text documentation. Clinical decision support rules embedded within the electronic health record automate alerting for critical values, significant trends, and protocol deviations, reducing the cognitive burden on individual clinicians and ensuring consistent application of safety protocols [36].

Accountability structures ensure that collaborative processes function as intended and that opportunities for improvement are systematically identified and addressed. Performance metrics for collaborative DIOT management might include process measures such as time from laboratory result availability to clinical action, completeness of medication reconciliation at transitions of care, and adherence to monitoring protocols for high-risk medications. Outcome measures might include rates of severe organ toxicity, incidence of drug discontinuation due to toxicity, and patient-reported outcomes related to medication safety and satisfaction. Regular review of these metrics by interprofessional quality improvement teams enables identification of performance gaps, development of targeted interventions, and evaluation of improvement efforts over time.

6. Implementation Challenges and Strategies for Success

The translation of collaborative frameworks from theoretical models to clinical reality confronts numerous challenges rooted in organizational culture, professional identity, resource constraints, and technological limitations. Anticipating these challenges and developing proactive strategies to address them significantly increases the likelihood of successful implementation and sustained collaborative practice.

Organizational culture represents perhaps the most fundamental determinant of collaborative success. Hierarchical structures that privilege physician authority over interprofessional input, departmental silos that inhibit cross-disciplinary communication, and reward systems that recognize individual achievement rather than team performance all impede collaborative practice. Transforming organizational culture requires sustained leadership commitment, visible modeling of collaborative behaviors by senior clinicians, and alignment of institutional policies and incentives with collaborative values. Leaders must articulate a compelling vision for interprofessional collaboration in drug safety monitoring, communicate that vision consistently across multiple forums, and hold themselves and others accountable for progress toward collaborative goals [37].

Professional identity and role perception present additional barriers to effective collaboration. Healthcare professionals are socialized within disciplinary silos, learning the values, norms, and boundaries of their profession through educational experiences that may emphasize professional uniqueness rather than interprofessional commonality. These professional identities, while fostering pride and commitment within disciplines, may inhibit cross-boundary collaboration by creating "turf" concerns, reinforcing stereotypes about other professions, and limiting willingness to engage in shared decision-making. Addressing these barriers requires interprofessional education initiatives that bring trainees from different disciplines together for shared learning experiences, clinical rotations that expose learners to collaborative practice models, and faculty development that equips educators to model and teach collaborative competencies.

Resource constraints, including limitations on personnel time, funding for collaborative infrastructure, and access to enabling technologies, present practical barriers to implementation. Collaborative workflows require time for interprofessional communication, case conferences, and quality improvement activities that may not be explicitly funded or scheduled. The electronic health record enhancements necessary to support collaborative monitoring, including clinical decision support rules, structured documentation templates, and interprofessional communication tools, require financial investment and technical expertise that may exceed available resources. Addressing these constraints requires creative approaches to resource allocation, including repurposing existing positions to support collaborative activities, leveraging technology to automate routine tasks and free professional time for higher-value collaborative work, and building the business case for collaboration through demonstration of improved outcomes and reduced costs.

Regulatory and legal considerations also influence collaborative practice, particularly regarding scope

of practice, professional liability, and documentation requirements. In many jurisdictions, scope-of-practice regulations limit the activities that non-physician professionals may perform independently, potentially constraining the ability of pharmacists and nurses to act on collaborative findings without physician oversight. Liability concerns may deter professionals from engaging in collaborative activities that extend beyond traditional role boundaries, particularly when responsibility for outcomes is unclear or when institutional policies fail to address collaborative practice explicitly. Addressing these barriers requires review and revision of institutional policies to support collaborative practice, development of collaborative practice agreements that specify roles and responsibilities, and engagement with regulatory bodies to ensure that scope-of-practice regulations facilitate rather than impede interprofessional teamwork.

Implementation strategies should address these challenges through multipronged approaches that combine structural changes, educational initiatives, technological enhancements, and cultural interventions. Pilot testing of collaborative workflows in selected clinical areas, with careful evaluation of processes and outcomes, enables refinement of approaches before broader dissemination and generates local evidence supporting expansion. Engaging frontline clinicians in collaborative design processes ensures that workflows reflect clinical reality and builds ownership and commitment among those who will implement them. Providing dedicated time and resources for collaborative activities signals institutional commitment and enables participation by busy clinicians. Celebrating early successes and sharing stories of improved patient outcomes builds momentum and reinforces the value of collaborative practice [38].

7. Conclusions

Drug-induced organ toxicity remains a persistent and consequential challenge in modern healthcare, contributing substantially to patient morbidity, healthcare costs, and limitations on therapeutic innovation. Laboratory professionals, nursing professionals, and pharmacy professionals each bring unique and indispensable contributions to the detection and management of DIOT, and the integration of these contributions into coherent collaborative workflows offers the best prospect for improving patient outcomes.

The framework proposed here represents a synthesis of evidence and experience from multiple domains, adapted to the specific requirements of drug safety monitoring. Its core elements—clearly defined roles, structured processes, reliable communication, and robust accountability—provide a template for collaborative practice that can be adapted to diverse clinical settings and organizational contexts. The challenges to implementation, while substantial, are not insurmountable, and the strategies outlined for addressing them offer practical guidance for organizations committed to advancing collaborative practice.

Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
- **Use of AI Tools:** The author(s) declare that no generative AI or AI-assisted technologies were used in the writing process of this manuscript.

References

[1] Omboni S., Caserini M. Effectiveness of pharmacist's intervention in the management of cardiovascular diseases. Open Heart. 2018;5(1)

[2] Jones C.D., Jones J., Richard A., Bowles K., Lahoff D., Boxer R.S., Masoudi F.A., Coleman E.A., Wald H.L. "Connecting the dots": a qualitative study of home health nurse perspectives on coordinating care for recently discharged patients. J. Gen. Intern. Med. 2017;32(10):1114–1121.

[3] McLean D.L., McAlister F.A., Johnson J.A. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN) Arch. Intern. Med. 2008;168:2355–2361.

[4] Peters M., Godfrey C., Khalil H., Mcinerney P., Parker D., Soares C. Guidance for conducting

systematic scoping reviews. Int. J. Evid. Based Healthc. 2015;13.

[5] Hadi M.A., Alldred D.P., Briggs M., Closs S.J. A combined nurse-pharmacist managed pain clinic: joint venture of public and private sectors. Int. J. Clin. Pharm. 2012;34(1):1–3.

[6] Flynn A., Anderson C. Meaningful collaboration. Nurs. Manag. 2012;43(12):2–5.

[7] Ploeg J., Canesi M., D Fraser K., McAiney C., Kaasalainen S., Markle-Reid M., Dufour S., Garland Baird L., Chambers T. Experiences of community-dwelling older adults living with multiple chronic conditions: a qualitative study. BMJ Open. 2019;9(3).

[8] Dennis S., May J., Perkins D., Zwar N., Sibbald B., Hasan I. What evidence is there to support skill mix changes between GPs, pharmacists and practice nurses in the care of elderly people living in the community? Australia & New Zealand Health Policy. 2009;6(7).

[9] D'Amour D., Ferrada-Videla M., San Martin Rodriguez L., Beaulieu M.-.D. The Conceptual basis for interprofessional collaboration: core concepts and theoretical frameworks. J. Interprof. Care. 2005;19(S1):116–131.

[10] Lee C.Y., Goeman D., Beanland C., Elliott R.A. Challenges and barriers associated with medication management for home nursing clients in Australia: a qualitative study combining the perspectives of community nurses. Community Pharmacists and GPs. Family Practice. 2018;36(3):332–342.

[11] Canadian Patient Safety Institute [CPSI]. (2017). Safety Improvement Projects.

[12] Engel J., Prentice D. The ethics of interprofessional collaboration. Nurs. Ethics. 2013;20(4):426–435.

[13] Celio J., Ninane F., Bugnon O., Schneider M.P. Pharmacist-nurse collaborations in medication adherence-enhancing interventions: a review. Patient Educ. Couns. 2018;101(7):1175–1192.

[14] Bell H.T., Granas A.G., Enmarker I., Omli R., Steinsbekk A. Nurses' and pharmacists' learning experiences from participating in interprofessional medication reviews for elderly in primary health care—A qualitative study. BMC Fam. Pract. 2017;18:1–9.

[15] Porter A.C., Fitzgibbon M.L., Fischer M.J., Gallardo R., Berbaum M.L., Lash J.P., Castillo S., Schiffer L., Sharp L.K., Tulley J., Arruda J.A., Hynes D.M. Rationale and design of a patient-centered medical home intervention for patients with end-stage renal disease on hemodialysis. Contemp. Clin. Trials. 2015;42:1–8.

[16] Alper, E., O'Malley, T.A., Greenwald, J. (2020). Hospital discharge and readmission.

[17] LeBlanc R.G., Choi J. Optimizing medication safety in the home. Home Healthc. Now. 2015;33(6):313–319.

[18] Pherson E., Roth J., Nkimbeng M., Boyd C., Szanton S.L. Ensuring safe and optimal medication use in older community residents: collaboration between a nurse and a pharmacist. Geriatr. Nurs. (Minneap) 2018;39(5):554–559.

[19] Bayraktar-Ekincioglu A., Kucuk E. The differences in the assessments of side effects at an oncology outpatient clinic. Int. J. Clin. Pharm. 2018;40(2):386–393.

[20] O'Daniel., M. & Rosenstein, A.H. (2008). Professional communication and team collaboration. In R.G. Hughes (Ed.), Patient Safety and Quality: An Evidence-Based Handbook for Nurses (Chapter 33). Rockville, MD: Agency for Healthcare Research and Quality (US).

[21] Lee C.Y., Beanland C., Goeman D., Petrie N., Petrie B., Vise F., Gray J., Elliott R.A. Improving medication safety for home nursing clients: a prospective observational study of a novel clinical pharmacy service— the visiting pharmacist (ViP) study. J. Clin. Pharmacy & Therapeutics. 2018;43(6):813–821.

[22] Perraudin C., Bourdin A., Spertini F., Berger J., Bugnon O. Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an interprofessional drug therapy management program. J. Clin. Immunol. 2016;36(5):502–510.

[23] Lyson, H.C., Sharma, A.E., Cherian, R., Patterson, E.S., McDonald, K.M., Lee, S.-.Y., & Sarkar, U. (2019). A qualitative analysis of outpatient medication use in community settings. J. Patient Safety: Publish Ahead of Print.

[24] Hunt R. Introduction to Community-based Nursing. 5th Ed. Lippincott Williams & Wilkins; 2012.

[25] Banning M. Medication management: older people and nursing. Nurs. Older People. 2005;17(7):20–23.

[26] Hadi M.A., Alldred D.P., Briggs M., Marczewski K., Closs S.J. Effectiveness of a community based nurse-pharmacist managed pain clinic: a mixed-methods study. Int. J. Nurs. Stud. 2016;53:219–227.

[27] Meyer-Massetti C., Hofstetter V., Hedinger-Grogg B., Meier C.R., Guglielmo B.J. Medication-related problems during transfer from hospital to home care: baseline data from Switzerland. Int. J. Clin. Pharm. 2018;40(6):1614–1620.

[28] Hohl C.M., Woo S.A., Cragg A., Wickham M.E., Ackerley C., Scheuermeyer F., Villanyi D. Repeat adverse drug events associated with outpatient medications: a descriptive analysis of 3 observational studies in British Columbia. Canada. CMAJ Open. 2019;7(3):E446–E453.

[29] Saint-Pierre C., Herskovic V., Sepúlveda M. Multidisciplinary collaboration in primary care: a systematic review. Fam. Pract. 2018;35(2):132–141.

[30] Institute for Safe Medication Practices Canada [ISMP Canada]. (2007). Definitions.

[31] Levac D., Colquhoun H., O'Brien K.K. Scoping studies: advancing the methodology. Implementation Sci. 2010;69(5).

[32] Arksey H., O'Malley L. Scoping studies: towards a methodological framework. Int. J. Soc. Res. Methodol. 2005;8(1):19–32.

[33] Ellenbecker C.H., Samia L., Cushman M.J., Alster K. Patient Safety and Quality in Home Health Care. 2009;1:40.

[34] Elliott R.A., Lee C.Y., Beanland C., Goeman D.P., Petrie N., Petrie B., Vise F., Gray J. Development of a clinical pharmacy model within an australian home nursing service using co-creation and participatory action research: the visiting pharmacist (ViP) study. BMJ Open. 2017;7(11).

[35] Hamano J., Ozone S., Tokuda Y. A comparison of estimated drug costs of potentially inappropriate medications between older patients receiving nurse home visit services and patients receiving pharmacist home visit services: a cross-sectional and propensity score analysis. BMC Health Serv. Res. 2015;15.

[36] Braungart C., Watson A., Rubin R. The effects of interprofessional collaboration on nurse managed warfarin program. J. Interprofessional Education & Practice. 2018;13:56–58.

[37] Godfrey, C.M., Harrison, M.B., Lang, A., Macdonald, M., Leung, T., & Swab, M. (2013). Homecare safety and medication management with older adults: a scoping review of the quantitative and qualitative evidence.

[38] Chapman E., Haby M.M., Toma T.S., de Bortoli M.C., Illanes E., Oliveros M.J., Barreto J.O. Knowledge translation strategies for dissemination with a focus on healthcare recipients: an overview of systematic reviews. Implementation Sci. 2020;15(1).